NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located worldwide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.

About NRG Oncology

NRG Oncology Clinical Trial GU005
Phase III IGRT and SBRT Verus Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

About the trial
NRG-GU005 will compare the side effects, both good and bad, of two different types of radiotherapy. The usual treatment for your type of prostate cancer is standard radiotherapy or surgery. Another form of radiotherapy is stereotactic body radiation therapy (SBRT). SBRT uses special equipment to position a participant and precisely deliver radiation to tumors in the body. Both the standard RT and SBRT treatments use daily images to guide the radiation treatment to protect normal tissue, however, SBRT will be delivered over a shorter amount of time. This study treatment may prevent the tumor from returning, but could also cause side effects. This clinical trial will determine if SBRT is better than standard radiotherapy for patients that have localized, intermediate risk prostate cancer.

Contact Information
NRG Oncology
Four Penn Center
1600 JFK Blvd., Suite 1020
Philadelphia, PA 19103
(215) 854-0716
info@nrgoncology.org

Stereotactic Body Radiotherapy and Prostate Cancer
What is a clinical trial?
Clinical Trials are research studies that look to find better ways to prevent, diagnose, or treat disease.

Who can join this study?
In addition to having localized, intermediate-risk prostate cancer, there are other eligibility requirements to participate in this study. Your doctor can determine if you meet these requirements.

Am I required to be in this study?
No. Taking part in this study is voluntary. You are free to choose to participate, not to participate, or to leave the study at any time. If you decide not to take part in this study, your doctor will discuss other treatment options with you.

What are the possible treatments?
All patients will be randomly assigned to two separate treatment groups. Group 1 will receive the standard of care radiotherapy. Group 2 will receive stereotactic body radiotherapy (SBRT).

How long will I be in this study?
If you are in group 1, you will receive 28 radiation treatments over approximately 6 weeks. If you are in group 2, you will receive 5 radiation treatments over approximately 2 weeks. For both groups, after you finish radiation your doctor will continue to watch you for side effects and follow your condition every 3 months for 2 years, then every 6 months for the next 3 years, and then yearly.

Are there side effects?
Possible risks for patients who receive radiation therapy for prostate cancer include need to urinate more frequently, urgency with urination, slower urinary flow, pain including with urination and/or bowel movements, hair lost in the treatment area which may be permanent, fatigue, and abnormal sexual function which may be permanent. Some less common, but more severe risks include chronic bowel/bladder symptoms, blood in urine, inability to control urine or bowel movements, diarrhea, bleeding of the rectum, and swelling or rash in the area of radiation.

More Information
You may visit the NCI website at cancer.gov for more information about studies or general information about cancer.
You may also call the NCI Cancer Information Service to get the same information at 1-(800)-4-CANCER (1-800-422-6237)